The UK's health cost body National Institute for Health and Clinical Excellence, or NICE, in its revised draft guidance did not recommend Swiss pharmaceutical giant Novartis' multiple sclerosis pill Gilenya, as it believes the drug would not be cost effective for the National Health Service, or NHS, in comparison with other available treatments. NICE has not yet issued guidance for the NHS.

Gilenya, or fingolimod, is a daily capsule that could reduce relapses in ...

I started Gilenya on Saturday. I don't know what I was expecting. I was a little fatigued the first couple of days. Other than that nothing has happened, good or bad. Just a not for anyone interested in starting.

First a little context / history.

I have had 3 CCSVI procedures, with little to no relief. I have tried ABX's, I was initially on REBIF, which failed for me. I have had MS Symptoms for around 15 years, with a diagnosis of MS for the past 8 years. I have two neurologists, with one saying SPMS, and the other saying RR. My EDSS is about 4.0 or higher. I can walk just over 1km. ...

Hi, to the forum:

Has anyone been thinking of taking both Gilenya and LDN?
Does anyone know if there are contraindications?
What a dilemma*
I would love to talk about it

Regards everyone.

Oral MS drug Gilenya® shows up to 71% reduction in annualised relapse rates



Novartis will showcase data from 13 abstracts on fingolimod (Gilenya®), at the 5th Joint Triennial Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) and Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) taking place from 19-22 October in Amsterdam.

The data being presented for fingolimod at ECTRIMS/ACTRIMS highlight the Novartis clinical trial program for ...

Japanese regulatory authorities have approved Novartis’ once-daily multiple sclerosis (MS) drug Gilenya.

The Gilenya sanction covers use of the drug for preventing relapse and delaying progression of physical disability in adult MS patients.

The only other drug licensed in Japan for preventing relapse of MS patients is interferon beta. ... Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1309

The first U.S. Food and Drug Administration-approved oral medication for multiple sclerosis poses a potential risk of macular edema, particularly in patients with a history of uveitis, according to a neuro-ophthalmologist.

MS patients who receive Gilenya (fingolimod, Novartis) should undergo baseline and follow-up examinations 3 to 4 months after initiation of treatment, Robert C. Sergott, MD, said at the Wills Eye Institute Alumni Conference in Philadelphia.

“The macular edema issue is one that we ...

Campaigners have expressed disappointment after the National Institute for Health and Clinical Excellence (Nice) rejected the first pill to treat multiple sclerosis.

The MS Society urged the medicines watchdog and drug firm Novartis to work together so that Gilenya – also called fingolimod – can be reappraised.

In draft guidance which is subject to consultation, Nice rejected the drug due to "uncertainties" over its effectiveness, a lack of appropriate data and concerns over cost-effectiveness. ...

Novartis Pharmaceuticals Corporation announced that the U.S. Food and Drug Administration’s approval of a supplemental New Drug Application (sNDA) for Gilenya™ (fingolimod) that includes T1 Gd-enhancing magnetic resonance imaging (MRI) data. Gilenya is a prescription medicine used to treat relapsing forms of multiple sclerosis (MS) in adults. It can decrease the number of MS flare-ups (relapses). It does not cure MS but can help slow down the physical problems that MS causes.

T1 Gd-enhancing ...

Oman has licensed the world's first oral medication for Multiple Sclerosis (MS), a move which medical experts say will improve medication tolerability and compliance for many of Oman's 200 MS sufferers.

The Oman Ministry of Health has approved the Novartis-made drug Gilenya (fingolimod) for use in the relapsing remitting form of MS that affects around two-thirds of those diagnosed with the disease, which causes muscle weakness, problems with coordination and impaired concentration.

Making the ...